M
Morichika Takita
Researcher at Tokyo University of Agriculture and Technology
Publications - 14
Citations - 200
Morichika Takita is an academic researcher from Tokyo University of Agriculture and Technology. The author has contributed to research in topics: Bone resorption & Osteoclast. The author has an hindex of 7, co-authored 14 publications receiving 177 citations.
Papers
More filters
Journal ArticleDOI
Nobiletin, a polymethoxy flavonoid, suppresses bone resorption by inhibiting NFκB-dependent prostaglandin E synthesis in osteoblasts and prevents bone loss due to estrogen deficiency.
Suguru Harada,Tsukasa Tominari,Chiho Matsumoto,Michiko Hirata,Morichika Takita,Masaki Inada,Chisato Miyaura +6 more
TL;DR: Nobiletin could be beneficial to bone health in postmenopausal women by suppressing the expression of cyclooxygenase-2, NFκB-dependent transcription, and prostaglandin E (PGE) production induced by IL-1 in osteoblasts.
Journal ArticleDOI
Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling that Drives Tumor Growth, Angiogenesis and Metastasis
Masaki Inada,Morichika Takita,Satoshi Yokoyama,Kenta Watanabe,Tsukasa Tominari,Chiho Matsumoto,Michiko Hirata,Yoshiro Maru,Takayuki Maruyama,Yukihiko Sugimoto,Shuh Narumiya,Satoshi Uematsu,Shizuo Akira,Gillian Murphy,Hideaki Nagase,Chisato Miyaura +15 more
TL;DR: The data show that B16 melanoma cells directly influence host stromal cells to generate PGE2 signals governing neoangiogenesis and metastatic growth in bone via osteoclast erosive activity as well as angiogenesis in soft tissue tumors.
Journal ArticleDOI
A novel carborane analog, BE360, with a carbon-containing polyhedral boron-cluster is a new selective estrogen receptor modulator for bone
Michiko Hirata,Masaki Inada,Chiho Matsumoto,Morichika Takita,Takumi Ogawa,Yasuyuki Endo,Chisato Miyaura +6 more
TL;DR: BE360 is a novel selective estrogen receptor modulator (SERM) that may offer a new therapy option for osteoporosis and restore bone loss in orchidectomized mice without androgenic action in the sex organs.
Journal ArticleDOI
Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.
TL;DR: Adding B16 cells induced osteoclast formation in the coculture of bone marrow cells and osteoblasts without any exogenous bone‐resorbing factor, and EP4 antagonist completely suppressed the osteocline formation induced by B 16 cells.
Journal ArticleDOI
Hyaluronan inhibits bone resorption by suppressing prostaglandin E synthesis in osteoblasts treated with interleukin-1.
Michiko Hirata,Megumi Kobayashi,Morichika Takita,Chiho Matsumoto,Chisato Miyaura,Masaki Inada +5 more
TL;DR: HA acts on osteoblasts to suppress the production of PGE2 and MMPs, and inhibits bone resorption, suggesting critical roles of HA in pathological bone loss with inflammation.